Home > Insider Trading > Filing (0001415889-24-006475)

Filing Details

Accession Number:: 0001415889-24-006475
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-03-04 21:22:22
Reporting Period:: 2024-02-29

Accepted Time:: 2024-03-04 21:22:22
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649094	Vaxcyte Inc.	PCVX	Biological Products, (No Disgnostic Substances) (2836)	464233385

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1960048	Elvia Cowan	C/O Vaxcyte, Inc. 825 Industrial Road, Suite 300 San Carlos CA 94070	Svp, Finance	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-02-29	5,400	$0.00	13,158	No	4	A	Direct
Common Stock	Acquisiton	2024-03-01	11,000	$25.92	24,158	No	4	M	Direct
Common Stock	Disposition	2024-03-01	2,322	$73.08	21,836	No	4	S	Direct
Common Stock	Disposition	2024-03-01	4,455	$73.69	17,381	No	4	S	Direct
Common Stock	Disposition	2024-03-01	4,901	$74.90	12,480	No	4	S	Direct
Common Stock	Disposition	2024-03-02	324	$71.55	12,156	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	F	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2024-02-29	25,000	$0.00	25,000	$73.82
Common Stock	Stock Option (right to buy)	Disposition	2024-03-01	11,000	$0.00	11,000	$25.92

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
25,000		2024-02-28	No	4	A	Direct
129,000		2032-08-08	No	4	M	Direct

Footnotes

Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
Includes 457 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2023.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023.
The price reported is a weighted-average price. The shares were sold at prices ranging from $72.39 to $73.365. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $74.465. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $74.47 to $75.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
1/4 of the shares subject to the option shall vest on July 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.